A detailed history of Jnba Financial Advisors transactions in Astrazeneca PLC stock. As of the latest transaction made, Jnba Financial Advisors holds 351 shares of AZN stock, worth $25,005. This represents 0.0% of its overall portfolio holdings.

Number of Shares
351
Previous 351 -0.0%
Holding current value
$25,005
Previous $27,000 18.52%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

SELL
$76.67 - $87.62 $100,054 - $114,344
-1,305 Reduced 78.8%
351 $27,000
Q2 2024

Jul 22, 2024

SELL
$66.81 - $80.83 $34,874 - $42,193
-522 Reduced 23.97%
1,656 $129,000
Q1 2024

Apr 26, 2024

SELL
$61.03 - $69.57 $244 - $278
-4 Reduced 0.18%
2,178 $147,000
Q3 2023

Nov 02, 2023

BUY
$64.85 - $71.7 $648 - $717
10 Added 0.46%
2,182 $147,000
Q2 2023

Aug 03, 2023

BUY
$69.91 - $75.81 $2,866 - $3,108
41 Added 1.92%
2,172 $155,000
Q4 2022

Feb 06, 2023

SELL
$54.21 - $70.44 $53,505 - $69,524
-987 Reduced 31.65%
2,131 $144,000
Q3 2022

Nov 07, 2022

SELL
$53.02 - $135.75 $7,210 - $18,462
-136 Reduced 4.18%
3,118 $171,000
Q2 2022

Jul 22, 2022

BUY
$59.26 - $71.14 $8,059 - $9,675
136 Added 4.36%
3,254 $215,000
Q1 2020

May 01, 2020

SELL
$37.79 - $51.33 $12,168 - $16,528
-322 Reduced 9.36%
3,118 $139,000
Q4 2019

Feb 10, 2020

BUY
$42.46 - $50.46 $13,672 - $16,248
322 Added 10.33%
3,440 $172,000
Q2 2019

Jul 26, 2019

BUY
$37.28 - $41.68 $11,034 - $12,337
296 Added 10.49%
3,118 $129,000
Q1 2019

May 01, 2019

BUY
$35.49 - $43.02 $86,666 - $105,054
2,442 Added 642.63%
2,822 $114,000
Q4 2018

Feb 07, 2019

SELL
$36.86 - $41.49 $737 - $829
-20 Reduced 5.0%
380 $14,000
Q3 2018

Nov 01, 2018

BUY
$34.76 - $39.72 $3,476 - $3,972
100 Added 33.33%
400 $16,000
Q2 2017

Aug 14, 2017

BUY
N/A
300
300 $10,000

Others Institutions Holding AZN

About ASTRAZENECA PLC


  • Ticker AZN
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 3,099,020,032
  • Market Cap $221B
  • Description
  • AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...
More about AZN
Track This Portfolio

Track Jnba Financial Advisors Portfolio

Follow Jnba Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jnba Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Jnba Financial Advisors with notifications on news.